MUNDIPHARMA
16.4.2024 11:01:35 CEST | Business Wire | Press release
Mundipharma and Vectura will now progress development of the reformulation of flutiform® (fluticasone propionate/formoterol fumarate) following long-term collaboration, planning and lab-scale development work. The reformulation will ultimately ensure a comparable effective product for patients and further reduce its impact on the environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416962162/en/
The product is an established pressurised metered-dose inhaler (pMDI) for the treatment of asthma, where the use of a combination product is appropriate, and has been available on the market for more than a decade.3
It currently uses the approved apaflurane hydrofluoroalkane 227 (HFA-227), a type of fluorinated greenhouse gas, as its propellant.3 European Union regulation on these types of gases aims to reduce their use, and therefore their emissions, by two-thirds by 2030.1
Work is already under way to source an alternative to the HFA-227 gas used in fluticasone propionate/formoterol fumarate pMDI. This new collaboration will revitalise the efforts to identify and switch to a more environmentally friendly propellant. If successful, this will result in a significantly lower impact on global warming and alignment with European Union regulation on fluorinated greenhouse gases.1
With more than 262 million people living with asthma globally, the reformulation of some asthma treatments to reduce carbon emissions could have a significant impact on the global carbon footprint.4,5
“We are dedicated to positively influencing the life of asthma patients across the globe. This is the first step in our long-term plan to develop a near-zero-emissions asthma inhaler. We are determined to achieve this before the European Union ban of HFA (hydrofluoroalkane) gases comes into effect, and our collaboration with Vectura demonstrates this, as well as our aim to an overall commitment to sustainable healthcare innovation,” said Yuri Martina, Chief Development and Medical Officer at Mundipharma.
“At Vectura, our priority is to ensure that patients prescribed fluticasone propionate/formoterol fumarate pMDI can continue to have access to this treatment. Using Vectura’s expertise and extensive track record in the development of inhaled prescription medicines and devices, we believe the collaboration with Mundipharma will enable us to meet our environmental responsibilities and enable patients to use fluticasone propionate/formoterol fumarate pMDI in the years to come,” said Geraldine Venthoye, Chief Scientific Officer, Vectura.
®: FLUTIFORM is a registered trademark of Jagotec AG used under licence by Mundipharma.
References
- Regulation (EU) No 517/2014 of the European Parliament and of the Council of 16 April 2014 on fluorinated greenhouse gases and repealing Regulation (EC) No 842/2006 Text with EEA relevance. Available at: https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=uriserv:OJ.L_.2014.150.01.0195.01.ENG (last accessed March 2024)
- flutiform® pMDI emissions manufacturing data, Q4 2022 – Q4 2023. Data on file.
- flutiform® Summary of Product Characteristics (SmPC). Last updated 13 April 2022. https://www.emcpi.com/pi/26954. (last accessed April 2024).
- Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-22
- NHS England, World Asthma Day: tackling climate change and improving respiratory care. Available at https://www.england.nhs.uk/blog/world-asthma-day-tackling-climate-change-and-improving-respiratory-care/ (last accessed March 2024)
*ENDS*
Job code: SciA-FLU-2400001| Date of preparation: April 2024
|
Notes to Editors
About flutiform® (fluticasone propionate/formoterol fumarate):
flutiform® is an inhaler (a pressurised metered-dose inhalation, suspension) which contains two active ingredients, fluticasone propionate and formoterol fumarate dihydrate.3 This fixed-dose combination of fluticasone propionate and formoterol fumarate (flutiform®) is indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β₂ agonist) is appropriate for the management of asthma symptoms.3
About Mundipharma:
Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America and the Middle East.
Mundipharma is dedicated to bringing innovative treatments to patients in the areas of respiratory, pain management, infectious disease as well as other severe and debilitating disease areas. Our guiding principles, centred around Integrity and Patient-Centricity, are at the heart of everything we do. For more information visit www.mundipharma.com.
About Vectura:
Vectura is a specialist inhalation contract development and manufacturing organization (CDMO) that provides inhaled drug development solutions to help customers bring their medicines to patients. With 25 years’ experience, it provides a combination of formulation science, device technology, and inhaled development expertise. Vectura is a member of the Vectura Fertin Pharma group of companies. For more information visit www.vectura.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416962162/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Outcome Economy at Work – New Research From Vertage15.10.2026 15:01:00 CEST | Press release
Outcome-ready businesses outperform on customer satisfaction, strategic delivery and speed to value – with a clear cultural edge; new Vertage research shows why, and how others can catch up Three in four enterprises (74%) define significant work around outcomes, but only 15% are ready to deliver it consistently, according to new global research from HR tech leader Vertage. These ‘outcome-ready’ enterprises report higher customer satisfaction (91% vs. 67%), stronger delivery of strategic goals (86% vs. 65%) and faster conversion of opportunities into value (85% vs. 64%). They also have a cultural edge: 69% of their employees understand their contribution and can adapt how they work, compared with 34% elsewhere. "AI adoption no longer separates strong businesses from the rest. Outcome readiness does," said Edzard Overbeek, Group CEO of Vertage. "The strongest businesses organize people, partners and AI around a clear result, and they keep human judgment at the center." The study, The Out
Introducing Ledger Atom™—Everything You Value, Finally Secure15.10.2026 14:45:00 CEST | Press release
Ledger Atom™ is a security and privacy device that runs your everyday apps, purpose-built to protect your most sensitive digital value, in a world where AI is challenging cybersecurity and authenticity at an unprecedented level. Ledger™, the global leader in secure infrastructure for digital ownership, today unveiled Ledger Atom™, a security and privacy device that runs your everyday apps, purpose-built to help protect your money, your AI agent approvals, and your privacy. The innovative architecture of Ledger Atom, leveraging Android™ open source alongside Ledger OS™, Ledger’s proprietary security-first operating system running on a secure element chip, allows you to approve sensitive actions in a secure environment while using all your everyday apps on a single device. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015445765/en/ Ledger has launched Ledger Atom, a security and privacy device that runs your everyday apps,
Meet Yuvo - The All-In-One Platform Helping Travel Brands Optimize Every Stage of Their Customer's Journey15.10.2026 14:36:00 CEST | Press release
The multi-service travel tech company gives OTAs, TMCs, airlines, insurers and fintechs one integration to add real-time flight data, disruption protection and travel add-ons to every trip. Yuvo data shows that flight disruption hit more than 913 million passengers in 2025, and travellers are now buying travel protection at six times the pre-pandemic rate. Yet for most travel brands, a delayed flight still means support calls, refunds and lost customers. Yuvo turns those moments, and every other step of the trip, into revenue and loyalty. Most travel brands earn from their customers only once: when they book. Yuvo changes that. It helps partners earn across the whole journey, with no technology to build and full control of the customer relationship. Yuvo works with some of the biggest names in travel, turning the customer relationships they already have into an ongoing revenue stream while keeping them fully in control. Built by a team of seasoned travel tech experts, the platform has
Visa Direct Launches Stablecoin-Powered Money Movement as Pilots Move to Production15.10.2026 14:00:00 CEST | Press release
Inyo Global becomes the first enabler to bring Visa Direct's stablecoin-enabled prefunding into production, making stablecoin-powered money movement available for businesses that run cross-border payments through Visa Direct. Today, Visa (NYSE: V) announced the next phase of its stablecoin strategy as Visa Direct stablecoin capabilities advance from pilot stage to commercial deployment. The milestone marks an important step in bringing stablecoin-enabled money movement into real-world commercial operations. In the initial rollout, Inyo Global, a Visa Direct processor, is the first enabler of this new offering, powering it for eligible Visa Direct clients and partners1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015116414/en/ Over the past year, Visa Direct has worked with clients and partners to explore how stablecoins can help improve the way businesses fund and move money across borders. As interest in faster, more
TreviPay Named a Leader in Two 2026 IDC MarketScape Assessments for AI-Enabled A/R Automation and Embedded Payments15.10.2026 14:00:00 CEST | Press release
TreviPay, a global B2B payments infrastructure partner, today announced it has been named a Leader in two 2026 IDC MarketScape assessments: the IDC MarketScape: Worldwide AI-Enabled Accounts Receivable Automation Applications for the Enterprise 2026 Vendor Assessment and the IDC MarketScape: Worldwide Embedded Payment Applications in Accounts Receivable Workflows 2026 Vendor Assessment. The recognition comes as enterprise finance teams look beyond automating individual A/R tasks toward coordinating the decisions and actions that drive growth and improve cash flow. We believe these assessments reflect a market in which payment execution, cash application, credit, collections and customer experience are valued when working together in one connected system. The IDC MarketScape for Worldwide AI-Enabled Accounts Receivable Automation Applications for the Enterprise noted the following strengths: Flexible risk retention options: A partnership with Mastercard lets clients offer net terms with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom